100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R41DA043974
Award Date
8/1/17
Completion Date
7/31/20
Dollars Obligated
$225K
Overview
Activity
4
Transactions
4
Subawards
Similar Awards
Federal Agency
National Institute on Drug Abuse
Awardee
Theranano LLC (JCU5WSZNSTF3)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Newton, MA 02459, USA
Update #1
Update #2
QUANTITATIVE NON-INVASIVE BRAIN IMAGING USING MAGNETIC NANOPARTICLES
Posted 7/31/17
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
QUANTITATIVE NON-INVASIVE BRAIN IMAGING USING MAGNETIC NANOPARTICLES - THIS PHASE I STTR PROJECT IS BASED UPON A NEW TECHNIQUE QUANTITATIVE ULTRA-SHORT TIME-TO-ECHO CONTRAST-ENHANCED (QUTE-CE) MRI UTILIZING UTE SEQUENCES WITH SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES (SPION) THAT LEADS TO QUANTIFIABLE VASCULAR IMAGES WITH UNPRECEDENTED CLARITY AND DEFINITION. QUTE-CE IS PARTICULARLY OPTIMAL USING FERUMOXYTOL, AN FDA APPROVED IRON-OXIDE NANOPHARMACEUTICAL. THE TECHNIQUE WAS DEVELOPED BY PI SRIDHAR AND HIS TEAM AT NORTHEASTERN UNIVERSITY. NORTHEASTERN UNIVERSITY HAS LICENSED THE QUTE-CE MRI METHOD TO THERANANO LLC FOR COMMERCIAL TRANSLATION. THE THERANANO QUTE-CE MRI PRODUCT IS AN IMAGING SUITE COMPRISED OF METHODS AND SOFTWARE FOR QUANTITATIVE NON-INVASIVE BRAIN IMAGING CUSTOMIZED FOR USE BY CLINICAL RADIOLOGISTS. THIS PHASE I STTR PROJECT WILL DEVELOP THE QUTE-CE MRI SUITE AND VALIDATE WITH FIRST-IN-HUMAN STUDIES. THE SPECIFIC AIMS OF THIS PROJECT ARE SUMMARIZED HERE. SPECIFIC AIM 1. DEVELOP AND OPTIMIZE QUTE-CE PROTOCOL FOR 3D CLINICAL IMAGING AT 3T. THIS PROJECT WILL PRIMARILY USE THE SIEMENS 3T TRIOTIM MRI SCANNER WITH 20-CHANNEL HEAD COIL. 3 TASKS WILL BE PURSUED TO DEVELOP THE OPTIMIZING PROTOCOL. TASK 1: DEVELOP A UTE IMAGING PROTOCOL. TASK 2: DEVELOP A ROBUST TRAJECTORY FOR IMPROVED IMAGE RECONSTRUCTION AND SIGNAL QUANTIFICATION. TASK 3: IMPLEMENT A ROBUST METHODOLOGY FOR ACCOUNTING FOR B1+ INHOMOGENEITY. SPECIFIC AIM 2. VALIDATE THE QUTE-CE NEUROIMAGING SUITE WITH STUDIES IN HEALTHY HUMAN SUBJECTS. THESE STUDIES WILL BE CARRIED OUT AT MASSACHUSETTS GENERAL HOSPITAL (MGH) UNDER THE DIRECTION OF DR. MUKESH HARISINGHANI, A WORLD RENOWNED EXPERT IN CLINICAL NANOPARTICLE IMAGING, AND DR. JOHN CHEN, AN EXPERT NEURO-RADIOLOGIST. THE STUDIES WILL HAVE FULL APPROVAL OF THE MGH IRB. 15 HEALTHY VOLUNTEERS WILL BE IMAGED IN THE SIEMENS TRIO 3T SCANNER WITH FERUMOXYTOL CONTRAST AGENT AND USING THE PROTOCOL OPTIMIZED IN AIM 1. BLOOD DRAWS WILL BE TAKEN BEFORE AND AFTER ADMINISTRATION FOR VALIDATION OF THE QUANTITATIVE ESTIMATION OF THE BLOOD CA. SPECIFIC AIM 3. DEVELOP THE QUTE-CE MRI SUITE FOR NON-INVASIVE QUANTITATIVE BRAIN IMAGING A RADIOLOGIST FRIENDLY SOFTWARE SUITE WILL BE DEVELOPED FOR PRESENTATION AND ANALYSIS OF THE SUBJECT SCANS. THE SUITE WILL PRESENT RESULTS FOR (1) WHOLE BRAIN ANGIOGRAPHY, (2) FULL BRAIN VOXEL BASED CEREBRAL BLOOD VOLUME (CBV) MAPS, (3) THE FIRST CBV MAP OF THE HUMAN BRAIN BY REGISTERING THE VOXULAR DATA ON A HUMAN BRAIN MAP. THE ANALYSIS WILL ALSO PROVIDE TIME-DEPENDENT DATA FOR THE BLOOD POOL CONCENTRATION OF CONTRAST AGENT, WHICH WILL BE CROSS-CHECKED WITH ELEMENTAL ANALYSIS OF THE BLOOD DRAW ASSAY. QUTE-CE MRI ADDRESSES THREE CRITICAL UNMET NEEDS: 1) POSITIVE CONTRAST IMAGING WITH A SAFE CONTRAST AGENT PROVIDING AN ALTERNATIVE TO GD BASED CONTRAST AGENTS THAT HAVE BEEN SHOWN TO BE TOXIC. 2) NON-INVASIVE LIVE WHOLE BRAIN VASCULAR IMAGING WITH EXCEPTIONAL CLARITY AND DEFINITION. 3) QUANTITATIVE MRI, WHERE AN ABSOLUTE MEASUREMENT OF CA CONCENTRATION IS ASSAYED, COMPETITIVE WITH NUCLEAR IMAGING BUT WITHOUT RADIATION TOXICITY. THE PROPOSED STUDIES SHOULD LEAD TO GROUNDBREAKING RESULTS ON BRAIN FUNCTION AND NEUROLOGICAL HEALTH.
$0
2/18/21
Not listed
QUANTITATIVE NON-INVASIVE BRAIN IMAGING USING MAGNETIC NANOPARTICLES - THIS PHASE I STTR PROJECT IS BASED UPON A NEW TECHNIQUE QUANTITATIVE ULTRA-SHORT TIME-TO-ECHO CONTRAST-ENHANCED (QUTE-CE) MRI UTILIZING UTE SEQUENCES WITH SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES (SPION) THAT LEADS TO QUANTIFIABLE VASCULAR IMAGES WITH UNPRECEDENTED CLARITY AND DEFINITION. QUTE-CE IS PARTICULARLY OPTIMAL USING FERUMOXYTOL, AN FDA APPROVED IRON-OXIDE NANOPHARMACEUTICAL. THE TECHNIQUE WAS DEVELOPED BY PI SRIDHAR AND HIS TEAM AT NORTHEASTERN UNIVERSITY. NORTHEASTERN UNIVERSITY HAS LICENSED THE QUTE-CE MRI METHOD TO THERANANO LLC FOR COMMERCIAL TRANSLATION. THE THERANANO QUTE-CE MRI PRODUCT IS AN IMAGING SUITE COMPRISED OF METHODS AND SOFTWARE FOR QUANTITATIVE NON-INVASIVE BRAIN IMAGING CUSTOMIZED FOR USE BY CLINICAL RADIOLOGISTS. THIS PHASE I STTR PROJECT WILL DEVELOP THE QUTE-CE MRI SUITE AND VALIDATE WITH FIRST-IN-HUMAN STUDIES. THE SPECIFIC AIMS OF THIS PROJECT ARE SUMMARIZED HERE. SPECIFIC AIM 1. DEVELOP AND OPTIMIZE QUTE-CE PROTOCOL FOR 3D CLINICAL IMAGING AT 3T. THIS PROJECT WILL PRIMARILY USE THE SIEMENS 3T TRIOTIM MRI SCANNER WITH 20-CHANNEL HEAD COIL. 3 TASKS WILL BE PURSUED TO DEVELOP THE OPTIMIZING PROTOCOL. TASK 1: DEVELOP A UTE IMAGING PROTOCOL. TASK 2: DEVELOP A ROBUST TRAJECTORY FOR IMPROVED IMAGE RECONSTRUCTION AND SIGNAL QUANTIFICATION. TASK 3: IMPLEMENT A ROBUST METHODOLOGY FOR ACCOUNTING FOR B1+ INHOMOGENEITY. SPECIFIC AIM 2. VALIDATE THE QUTE-CE NEUROIMAGING SUITE WITH STUDIES IN HEALTHY HUMAN SUBJECTS. THESE STUDIES WILL BE CARRIED OUT AT MASSACHUSETTS GENERAL HOSPITAL (MGH) UNDER THE DIRECTION OF DR. MUKESH HARISINGHANI, A WORLD RENOWNED EXPERT IN CLINICAL NANOPARTICLE IMAGING, AND DR. JOHN CHEN, AN EXPERT NEURO-RADIOLOGIST. THE STUDIES WILL HAVE FULL APPROVAL OF THE MGH IRB. 15 HEALTHY VOLUNTEERS WILL BE IMAGED IN THE SIEMENS TRIO 3T SCANNER WITH FERUMOXYTOL CONTRAST AGENT AND USING THE PROTOCOL OPTIMIZED IN AIM 1. BLOOD DRAWS WILL BE TAKEN BEFORE AND AFTER ADMINISTRATION FOR VALIDATION OF THE QUANTITATIVE ESTIMATION OF THE BLOOD CA. SPECIFIC AIM 3. DEVELOP THE QUTE-CE MRI SUITE FOR NON-INVASIVE QUANTITATIVE BRAIN IMAGING A RADIOLOGIST FRIENDLY SOFTWARE SUITE WILL BE DEVELOPED FOR PRESENTATION AND ANALYSIS OF THE SUBJECT SCANS. THE SUITE WILL PRESENT RESULTS FOR (1) WHOLE BRAIN ANGIOGRAPHY, (2) FULL BRAIN VOXEL BASED CEREBRAL BLOOD VOLUME (CBV) MAPS, (3) THE FIRST CBV MAP OF THE HUMAN BRAIN BY REGISTERING THE VOXULAR DATA ON A HUMAN BRAIN MAP. THE ANALYSIS WILL ALSO PROVIDE TIME-DEPENDENT DATA FOR THE BLOOD POOL CONCENTRATION OF CONTRAST AGENT, WHICH WILL BE CROSS-CHECKED WITH ELEMENTAL ANALYSIS OF THE BLOOD DRAW ASSAY. QUTE-CE MRI ADDRESSES THREE CRITICAL UNMET NEEDS: 1) POSITIVE CONTRAST IMAGING WITH A SAFE CONTRAST AGENT PROVIDING AN ALTERNATIVE TO GD BASED CONTRAST AGENTS THAT HAVE BEEN SHOWN TO BE TOXIC. 2) NON-INVASIVE LIVE WHOLE BRAIN VASCULAR IMAGING WITH EXCEPTIONAL CLARITY AND DEFINITION. 3) QUANTITATIVE MRI, WHERE AN ABSOLUTE MEASUREMENT OF CA CONCENTRATION IS ASSAYED, COMPETITIVE WITH NUCLEAR IMAGING BUT WITHOUT RADIATION TOXICITY. THE PROPOSED STUDIES SHOULD LEAD TO GROUNDBREAKING RESULTS ON BRAIN FUNCTION AND NEUROLOGICAL HEALTH.
$0
2/18/21
Not listed
QUANTITATIVE NON-INVASIVE BRAIN IMAGING USING MAGNETIC NANOPARTICLES
$0
7/17/19
Not listed
QUANTITATIVE NON-INVASIVE BRAIN IMAGING USING MAGNETIC NANOPARTICLES
$225.2k
7/31/17